Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 32-week Randomised, Multinational, Treat-to-target, Open Label, Parallel Group Comparison of Stepwise Insulin Intensification of Biphasic Insulin Aspart (BIAsp) 30 and Basal-bolus Therapy With Insulin Glargine and Insulin Aspart in Insulin naïve Type 2 Diabetic Patients Inadequately Controlled on Oral Anti-diabetic Therapy

NCT02453685 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT02453685
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02453685 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 32-week Randomised, Multinational, Treat-to-target, Open Label, Parallel Group Comparison of Stepwise Insulin Intensification of Biphasic Insulin Aspart (BIAsp) 30 and Basal-bolus Therapy With Insulin Glargine and Insulin Aspart in Insulin naïve Type 2 Diabetic Patients Inadequately Controlled on Oral Anti-diabetic Therapy
Lead sponsor
Novo Nordisk A/S
Phase
Phase 4
Overall status
Completed
Start date
August 31, 2015
Completion date
September 20, 2016
Enrollment
335 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 2